Why the study?
Does torasemide added to standard therapy improve electrical instability of the heart in patients with ischemic mitral regurgitation post myocardial infarction?
Does torasemide added to standard therapy improve electrical instability of the heart in patients with ischemic mitral regurgitation post myocardial infarction?
Adding torasemide to standard post-MI therapy in patients with ischemic mitral regurgitation reduces episodes of myocardial ischemia and improves electrical stability of the heart.
Answers are grounded in this paper and cite their sources.
Supports adjunctive torasemide post-MI with ischemic MR to reduce ischemia; extends loop diuretic evidence beyond diuresis in RCTs.
Aim. To assess the efficacy of torasemide for changes of electrical instability of the heart in patients with ischemic mitral regurgitation during the period after myocardial infarction. Material and methods. Ninety six patients with mitral regurgitation, with Q-myocardial infarction (Q-MI) had been randomized to two groups. During six months after discharge, in the control group 1, of 46 patients, the standard therapy applied (clopidogrel, acetylsalicylic acid, nebivolol, perindopril). In the study group 2, of 50 patients, additionally torasemide was used. At baseline, in 3 and 6 months Holter ECG monitoring was performed. Results. In the group 1 patients with mitral regurgitation post Q-MI, with the standard treatment, there was decrease of silent myocardial ischemia (3,6±0,5 — baseline; 3,3±0,5 and 3,1±0,3 — in 3 and 6 months, respectively, p<0,05). They showed decrease of the duration of silent and anginal ischemia, depression of ST segment >1 mm, number of patients with supra- and ventricular extrasystoles (p>0,05) and increase of the number of anginal ischemia (2,1±0,4 — baseline, 2,2±0,2 and 2,3±0,1 — in 3 and 6 months, respectively, p>0,05). In the group 2 patients, in 6 months of treatment there was decrease of number of silent (2,1±0,3) ischemia episodes, duration of anginal (7,3±2,1 min) and silent (4,3±1,2 min) ischemia comparing to baseline (8,8±1,2; 10,6±2,7 and 8,8±1,2 min — respectively, p<0,05). Also, they showed decrease of ST depression >1 mm episodes (1,2±0,2 vs 2,0±0,4 mm at baseline) and relative values of the patients number with the registered supra- and ventricular extrasystoles (38% and 44%, respectively, versus 62% and 84% at baseline, p>0,05). Conclusion. The usage of torasemide combination with standard treatment decreases the number of episodes, duration of silent and anginal myocardial ischemia, rate of registered supra- and ventricular extrasystoles in mitral regurgitation patients post Q-MI, comparing to separate standard treatment. Also, the rate of anginal ischemia episodes does not change in 3 and 6 months of standard treatment.
No takes yet. Share an insight, caveat, or question.
Ibragimova et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: